David A. Rewolinski

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini et al. · Clinical Cancer Research · 2008 · 620 citations

Thioether benzenesulfonamide inhibitors of carbonic anhydrases II and IV: Structure-based drug design, synthesis, and biological evaluation

William F. Vernier, Wesley K. M. Chong, David A. Rewolinski et al. · Bioorganic & Medicinal Chemistry · 2010 · 41 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Biochemistry +12

Evaluation of CXCR4 Inhibition in the Prevention and Intervention Model of Laser-Induced Choroidal Neovascularization

Edwin Lee, David A. Rewolinski · Investigative Ophthalmology & Visual Science · 2010 · 36 citations

Ocular Disease, Biomedical Engineering, Regenerative Medicine +17

Prostaglandin E ₂ –Induced Aldosterone Release Is Mediated by an EP ₂ Receptor

Stephen Csukas, Craig J. Hanke, David A. Rewolinski et al. · Hypertension · 1998 · 29 citations · Full text

Design, Synthesis, and Evaluation of NO-Donor Containing Carbonic Anhydrase Inhibitors To Lower Intraocular Pressure

Qinhua Huang, Eugene Rui, Morena Cobbs et al. · Journal of Medicinal Chemistry · 2015 · 29 citations · Full text

Medicinal Chemistry, Ocular Disease, Anti-inflammatory +15